Tonix Pharmaceuticals has been granted a patent for a method to treat major depressive disorder in fibromyalgia patients using cyclobenzaprine. The treatment involves administering less than 5 mg/day of cyclobenzaprine, either alone or with an antidepressant, to alleviate symptoms of depression. GlobalData’s report on Tonix Pharmaceuticals Holding gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tonix Pharmaceuticals Holding, Cancer treatment biomarkers was a key innovation area identified from patents. Tonix Pharmaceuticals Holding's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11998516B2 outlines a novel method for treating major depressive disorder specifically in patients suffering from fibromyalgia. The method involves administering a pharmaceutical composition that includes cyclobenzaprine, or a pharmaceutically acceptable or water-soluble salt of cyclobenzaprine, along with a suitable carrier. Notably, the treatment is characterized by a low dosage of cyclobenzaprine, specifically less than 5 mg per day, with an option for even lower doses of less than 2.5 mg per day. The claims emphasize that this treatment approach can effectively ameliorate or eliminate symptoms of major depressive disorder in the targeted patient population.
Additionally, the patent claims provide flexibility in the administration of the pharmaceutical composition. It can be given either sequentially or concurrently with other antidepressant medications, enhancing its therapeutic potential. The formulation can be delivered in various forms, such as orally dissolving tablets or thin film formulations, catering to patient preferences and compliance. Furthermore, the method may be combined with psychotherapeutic interventions and is suggested to be administered at bedtime, potentially optimizing the treatment's efficacy and patient comfort. This patent thus presents a comprehensive approach to addressing the intersection of fibromyalgia and major depressive disorder through a specific pharmacological strategy.
To know more about GlobalData’s detailed insights on Tonix Pharmaceuticals Holding, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
